| long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human t cell leukaemia virus type i envelope gene. | to develop effective vaccines against infection with human t cell leukaemia virus type i (htlv-i), we constructed a recombinant vaccinia virus (wr-sfb5env) synthesizing the htlv-i envelope (env) gp46 protein under the control of a strong promoter, termed the ati hybrid promoter. wr-sfb5env expressed a large quantity of gp46. in cynomolgus monkeys (macaca fascicularis) immunized with wr-sfb5env, anti-htlv-i env antibody, including neutralizing antibody, was induced and remained at a high level un ... | 1997 | 9010298 |
| evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the f or g glycoprotein of respiratory syncytial virus. | it has been shown previously that immunization with recombinant vaccinia viruses expressing the f or g envelope glycoprotein of human respiratory syncytial virus (rsv) strain a2 induced a protective immune response in the lower respiratory tract of cotton rats against live rsv challenge. as a continuation of these studies, the safety, immunogenicity and efficacy of these recombinant vaccinia viruses was evaluated in non-human primates. rhesus and patas monkeys were each inoculated intradermally ... | 1988 | 3072795 |
| cloning and expression of foreign genes in vaccinia virus, using a host range selection system. | a simple selection system has been developed for the cloning and expression of open reading frames in vaccinia virus. the selection system is based on a conditional lethal (host range) mutant of vaccinia virus. a deletion mutant of the vaccinia virus wr strain was generated by insertion of the neomycin resistance gene from transposon tn5 and selection with the antibiotic g418. this deletion recombinant, vp293, lacked approximately 21.7 kilobases of dna beginning 3.8 kilobases from the left end o ... | 1989 | 2547999 |
| spi-1 is a missing host-range factor required for replication of the attenuated modified vaccinia ankara (mva) vaccine vector in human cells. | modified vaccinia virus ankara (mva) is the leading poxvirus vector for development of vaccines against diverse infectious diseases. this distinction is based on high expression of proteins and good immunogenicity despite an inability to assemble infectious progeny in human cells, which together promote efficacy and safety. nevertheless, the basis for the host-range restriction is unknown despite past systematic attempts to identify the relevant missing viral gene(s). the search for host-range f ... | 2019 | 31145755 |